These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28083929)

  • 1. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
    Yang F; Yang Y; Wang Q; Wang Z; Miao Q; Xiao X; Wei Y; Bian Z; Sheng L; Chen X; Qiu D; Fang J; Tang R; Gershwin ME; Ma X
    Aliment Pharmacol Ther; 2017 Mar; 45(5):733-743. PubMed ID: 28083929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical performance of AMA-M2, anti-gp210 and anti-sp100 antibody levels in primary biliary cholangitis: When detected by multiplex bead-based flow fluorescent immunoassay.
    Wang Z; Li Y; Ren L; Li Y; Xu T; Li W; Gao W; Sun G; Liu M
    Immun Inflamm Dis; 2024 Jan; 12(1):e1161. PubMed ID: 38270327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio.
    Yoo JJ; Cho EJ; Lee B; Kim SG; Kim YS; Lee YB; Lee JH; Yu SJ; Kim YJ; Yoon JH
    Gut Liver; 2018 Nov; 12(6):714-721. PubMed ID: 30400732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms.
    Wang X; Yang Z; Ran Y; Li L; Wang B; Zhou L
    Ann Hepatol; 2023; 28(5):101121. PubMed ID: 37302574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.
    Haldar D; Janmohamed A; Plant T; Davidson M; Norman H; Russell E; Serevina O; Chung K; Qamar K; Gunson B; Hansen B; Richter A; Trivedi PJ; Hirschfield GM
    Liver Int; 2021 Mar; 41(3):535-544. PubMed ID: 33022821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis.
    Huang C; Han W; Wang C; Liu Y; Chen Y; Duan Z
    Dis Markers; 2019; 2019():9121207. PubMed ID: 31737133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China.
    Chen Q; Zhong R; Dong K; Wang Y; Kui Y; Ma B; Wen X; Jin Q
    Dig Liver Dis; 2022 Aug; 54(8):1094-1100. PubMed ID: 34789400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS).
    Nguyen HH; Shaheen AA; Baeza N; Lytvyak E; Urbanski SJ; Mason AL; Norman GL; Fritzler MJ; Swain MG
    PLoS One; 2018; 13(3):e0193960. PubMed ID: 29554146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune Markers in Primary Biliary Cholangitis.
    Shah SK; Bowlus CL
    Clin Liver Dis; 2024 Feb; 28(1):93-101. PubMed ID: 37945165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
    Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
    Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of increased serum stromal cell-derived factor-1 for primary biliary cholangitis.
    Yang Z; Liang Y; Lin F; Zhang Z; Luo W; Zhang Y; Zhong R
    Int Immunopharmacol; 2018 Mar; 56():285-290. PubMed ID: 29414663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis.
    Jaskowski TD; Nandakumar V; Novis CL; Palmer M; Tebo AE
    Clin Chim Acta; 2023 Feb; 540():117219. PubMed ID: 36610465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis.
    Itoh S; Ichida T; Yoshida T; Hayakawa A; Uchida M; Tashiro-Itoh T; Matsuda Y; Ishihara K; Asakura H
    J Gastroenterol Hepatol; 1998 Mar; 13(3):257-65. PubMed ID: 9570238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of clinical characteristics in patients with gp210 antibody-positive primary biliary cholangitis].
    Huang CY; Liu YM; Liu H; Xu B; Yan HP; Zhang HP; Liao HY; Zhang XD; Zhao J; Li WJ; Duan ZP
    Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):419-425. PubMed ID: 35545568
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of autoantibodies in the clinical management of primary biliary cholangitis.
    Rigopoulou EI; Bogdanos DP
    World J Gastroenterol; 2023 Mar; 29(12):1795-1810. PubMed ID: 37032725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The External Validation of GLOBE and UK-PBC Risk Scores for Predicting Ursodeoxycholic Acid Treatment Response in a Large U.S. Cohort of Primary Biliary Cholangitis Patients.
    Marenco-Flores A; Rojas Amaris N; Kahan T; Sierra L; Barba Bernal R; Medina-Morales E; Goyes D; Patwardhan V; Bonder A
    J Clin Med; 2024 Aug; 13(15):. PubMed ID: 39124763
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased sensitivity of gp210 autoantibody detection using a newly designed gp210 antigen.
    Xu J; Zhang H; Wang C; Jiang P; Han C; Dai Y; Qiu F; Gong Y; Jiang Y; Xu P; Zhang M; Zhang L; Shi X; Chen S; Tian Y; Seldin MF; Gershwin ME; Liu X; Li L
    J Immunol Methods; 2022 Feb; 501():113211. PubMed ID: 34971632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland.
    Terziroli Beretta-Piccoli B; Stirnimann G; Cerny A; Semela D; Hessler R; Helbling B; Stickel F; Kalid-de Bakker C; Bihl F; Giostra E; Filipowicz Sinnreich M; Oneta C; Baserga A; Invernizzi P; Carbone M; Mertens J
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):295-306. PubMed ID: 29181702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of autoimmune liver disease related autoantibodies in Chinese patients with primary biliary cirrhosis.
    Hu C; Deng C; Song G; Zhang W; Zhang S; Li X; Li P; Zhang F; Li Y
    Dig Dis Sci; 2011 Nov; 56(11):3357-63. PubMed ID: 21660486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.